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This paper discusses the toxicity and antidotal effects of 32 compounds. Screening studies have shown 
that these compounds combined with atropine are effective antidotes against the organophosphate 
nerve agents Tabun and/or Soman, having a therapeutic factor equal or greater than 2.0 when tested in 
mice or rats. We analysed the results of these studies, and recommend that these compounds should be 
studied in more detail simultaneously with conventional antidotes (PAM-2, HI-6, Toxogonin, TMB-4) in 
order to assess whether they could broaden the choice of compounds now available for the treatment of 
organophosphate poisoning.
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Treatment of organophosphate (OP) poisoning is 
still a problem, particularly when the OP warfare nerve 
agents Sarin, Soman, Tabun and VX are concerned. The 
current standard treatment of OP poisoning includes 
atropine as an antimuscarinic drug and oximes as 
reactivators of inhibited acetylcholinesterase (AChE). 
The mono- and bis-pyridinidum oximes PAM-2,
Toxogonin, HI-6 and TMB-4 are conventional standard 
oximes used as reactivators of the inhibited AChE. 
While the conventional oximes have been considered 
sufficiently effective against Sarin and VX, they are 
rather ineffective against Tabun and Soman (cf.1).
We have recently reviewed the synthesis and some 
biochemical properties of 158 compounds which had 
been prepared to test their interaction with native 
and phosphylated cholinesterases, and as antidotes 
against OP compounds (2). These compounds had 
been synthesized in Croatian laboratories over the past 
three decades. Only some compounds were studied 
in detail, while most were only screened for reactions 
with cholinesterases and as antidotes against OP 
warfare nerve agents in mice or rats.
Of 158 reviewed compounds, 28 were tested 
as antidotes against Tabun and 44 against Soman 
poisoning. Of those, we selected 32 compounds that 
showed a therapeutic effect in mice or rats, that is, 
a therapeutic factor equal or greater than 2.0. Here 
we present individual results obtained with these 
compounds (applied together with atropine), as well as 
data on their toxicity for the test animals. These data 
have not been summarised in our earlier review (2).
TESTING PROTOCOL
The acute toxicity and the antidotal effect of the 
compounds were tested in male albino mice (18 g 
Reiner E, Simeon-Rudolf V. ANTIDOTES AGAINST TABUN AND SOMAN
Arh Hig Rada Toksikol 2006;57:171-179
172
to 25 g b.w.) or rats (180 g to 200 g b.w.). The acute 
toxicity was expressed as the LD50 based on the 24-
hour mortality. The antidotal effect was expressed as 
the therapeutic factor (TF) which is the ratio between 
the LD50 of the OP compound in the presence and in 
the absence of antidotes:
TF = LD50(OP plus antidote) / LD50(only OP)
The OPs Tabun or  Soman were  g iven 
subcutaneously. The studied compounds were 
applied intraperitoneally (i.p.) or intramuscularly 
(i.m.) together with 10 mg kg-1 atropine sulphate. The 
antidotes were applied within less than one minute 
after the OP compound. The LD50values of the studied 
compounds and OPs were calculated from the results 
obtained with 4 to 6 different doses applied to 4 or 6 
animals per dose.
TOXICITY AND ANTIDOTAL EFFECTS
The studied antidotes were mono- or bis-
pyridinium (Py), imidazolium (Im) or quinuclidinium 
(Q) compounds, or compounds which contain 
two different moieties in the same molecule (PyIm, 
PyQ or ImQ). Their structures are given in Table 1. 
Table 1  Structure and Chemical Abstract Service Registry Number (CAS RN) of the compounds. References refer to the synthesis. Abbreviations
and CAS RN are taken from Ref. (1).
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Table 1  continued
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Table 1  continued
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All compounds, except Q-2 and Q-4, are oximes. 
Two compounds, Q-4 and ImQ-4, are carbamates. 
The abbreviations used in this paper are taken 
from reference (2). For the sake of comparison 
the structures, abbreviations and names of the 
conventional antidotes are shown in Table 2.
Table 3  Acute toxicity (LD
50





mg kg-1 mol kg-1
Py-2 71(*) 271(*) 15
Py2-2 250 404 16
Py2-4 197 323 16
Py2-6 191 309 16
Py2-8 179 293 16
Py2-42 170 292   5
Py2-43 132 226   5
Py2-87 33.4 70 17
Im-2 182 682 18
Im2-13 4.7 8.2 19
Im2-16 21 30 20
Im2-25 4.7 8.2 18
Q-1 56 208 12
Q-2 56 210 18
Q-4 144 424 18
Q2-1 224 388 12
PyIm-13 19 31 20
PyQ-1 >1000 >1830 12
PyQ-2 >200 >369 12
PyQ-3 >100 >179 12
PyQ-4 107 191 12
ImQ-2 283 775 18
ImQ-4 202 464 18
ImQ-5 225 498 13
The i.p. toxicity of 24 compounds is listed in Table 
3. Expressed on a molar basis, LD50 ranged from 
8 mol kg-1 to about 1800 mol kg-1. The most toxic 
compounds were two bis-imidazolium compounds, 
Im2-13 and Im2-25. Their toxicities almost approached 
the molar toxicity of the nerve agents. Such high 
toxicities on mice were also reported for a series of 
other prepared bis-imidazolium compounds (11). The 
second highest toxicity reported was for Im2-16 and 
PyIm-13, while all other compounds had LD50 above 
200 mol kg-1. The LD50 of the conventional oximes, 
determined using the same protocol as reported for 
compounds in Table 3, were between 200 mol kg-1
and 1900 mol kg-1 (6, 15-17, 21, 22).
All 32 compounds were tested as antidotes against 
Soman, and 21 of those also against Tabun (Table 
4). The best antidotal effect was reported for ImQ-4, 
which had TF values 5.3 and 4.3 against Soman and 
Tabun respectively. TF values between 3.0 and 3.4 
against both Soman and Tabun were reported for Q-
4 and Py2-42. Four compounds (Im-3, Im2-2, PyIm-5 
and PyIm-6) had TF values between 3.6 and 4.9, but 
only against Tabun.
DISCUSSION
The major cause of OP toxicity is the phosphylation 
of serine in the catalytic site of acetylcholinesterase, 
whereby AChE becomes inhibited. The inhibited AChE 
can be reactivated by oximes which dephosphylate 
the enzyme. Oximes are therefore used as antidotes 
against OP poisoning. Protectors of AChE from OP 
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inhibition are carbamates which carbamoylate the 
catalytic-site serine of AChE. Unlike the phosphylated 
AChE conjugate, the carbamoylated conjugate is 
very unstable, but still enough stable to ensure the 
protection of AChE against OP. Some carbamates are 
therefore used as prophylaxis/preatreatment against 
OP poisoning. Current knowledge of prophylactic 
and therapeutic treatment of OP poisoning has been 
summarized in many reviews (cf. 1, 23-26).
Antidotes against OP poisoning were developed 
soon after the OP warfare nerve agents were 
synthesized. In the early 1950s, PAM-2 was prepared 
and studied as an antidote (cf. 27). Later, bis-
pyridinium compounds were prepared with one or 
two oxime groups (HI-6, Toxogonin, TMB-4) (cf. 28), 
and were shown to be more effective than PAM-2. 
Grifantini et al. (29) introduced the imidazolium 
moiety into the oxime antidotes. During the 1980s, a 
series of quinuclidinium compounds, with or without 
an oxime group, were tested as antidotes due to the 
antimuscarinic properties of quinuclidinium (30, 31).
Compounds listed in Table 1 were described 
by their authors either as new compounds or as 
compounds analogous to those previously published. 
Some of those belong structurally to the series known 
under the abbreviations HGG, BDB, BMR, BMP 
or AB, according to the authors who prepared the 
compounds. In some papers the compounds were 
simply marked by capital letters or Roman numbers. In 
order to avoid ambiguity, we have not used the original 
abbreviations of the authors. Instead, in this paper we 
use abbreviations introduced in our previous review 
(2) that indicate the basic chemical structure which is 
pyridinium, imidazolium and quinuclidinium. 
As shown in Table 4, the best antidotal effect 
was achieved with ImQ-4, which is a carbamoylated 








Py-2 - 2.0 (*) 200 mol kg-1 15
Py2-2 2.8 2.9 30 mol kg
-1 16
Py2-4 2.5 2.6 30 mol kg
-1 16
Py2-6 2.1 2.1 30 mol kg
-1 16
Py2-8 2.4 3.3 30 mol kg
-1 16
Py2-42 3.0 3.4 30 mol kg
-1 5
Py2-43 <2.0 2.3 30 mol kg
-1 5
Py2-62 <2.0 2.0 30 or 15 mol kg
-1 6
Py2-66 2.0 2.9 30 or 15 mol kg
-1 6
Py2-67 2.3 <2.0 30 mol kg
-1 6
Py2-68 2.2 2.9 30 mol kg
-1 6
Py2-87 2.4 2.5 1/4 LD50 17
Im-2 <2.0 2.0 1/4 LD50 18
Im-3 3.6 (*)(**) <2.0 (*)(**) 30 mol kg-1 9
Im2-2 4.9 (*)(**) <2.0 (*)(**) 30 mol kg
-1 9
Im2-13 - 2.4 1/4 LD50 19
Im2-16 - 2.2 1/4 LD50 20
Im2-25 3.8 2.4 1/4 LD50 18
Q-1 - 3.2 1/4 LD50 12
Q-2 <2.0 2.3 1/4 LD50 18
Q-4 3.2 3.2 1/4 LD50 18
Q2-1 - 3.3 1/4 LD50 12
PyIm-5 4.2 (*)(**) <2.0 (*)(**) 30 mol kg-1 9
PyIm-6 4.4 (*)(**) <2.0 (*)(**) 30 mol kg-1 9
PyIm-13 - 2.0 1/4 LD50 20
PyQ-1 - 2.7 50 mol kg-1 12
PyQ-2 - 3.8 50 mol kg-1 12
PyQ-3 - 2.5 50 mol kg-1 12
PyQ-4 - 2.8 1/4 LD50 12
ImQ-2 2.4 2.8 1/4 LD50 18
ImQ-4 4.3 5.3 1/4 LD50 18
ImQ-5 - 2.4 1/4 LD50 13
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quinuclidinium/imidazolium compound with an oxime 
group in the molecule. The corresponding ImQ-2 
compound, which is not a carbamate, but has an 
oxime group, was much less effective against both 
Tabun and Soman. Compound Q-4, a carbamoylated 
quinuclidinium compound without an oxime group, 
was as good as its analogue Q-1, which has an oxime 
group instead of the carbamoyl group. However, Q-2, 
being no carbamate and having no oxime group, was 
ineffective against Tabun and only slightly effective 
against Soman. These results are in line with the 
known prophylactic properties of carbamates against 
OP poisoning.
Most TF values presented in Table 4 were evaluated 
with doses of antidotes that were not equitoxic (cf. 
Table 3 vs. Table 4). Only 14 compounds were 
applied at equitoxic doses, i.e. 1/4 of their LD50. For 
eight compounds no LD50 was determined. All other 
compounds were applied at a given dose irrespective 
of their toxicity. Due to this fact, most TF values 
listed in Table 4 can only be considered as screening 
values. However, they do indicate that the tested 
compounds have an antidotal effect against Soman 
and/or Tabun.
Only several authors (6, 9, 16, 17, 18, 21) 
have tested the conventional antidotes (Table 2) 
simultaneously with the compounds listed in Table 
1. They applied the testing protocol outlined in this 
paper. With one exception (17), conventional antidotes 
were applied at a given dose irrespective of their 
toxicity. PAM-2 was ineffective against both Tabun 
and Soman (9, 21). The highest reported TF values 
were 7.1 with TMB-4 against Tabun, and 4.7 with HI-6 
against Soman; the applied dose of TMB-4 and HI-6 
was 1/4 of their LD50 values (17). The next highest TF 
value against Tabun was 5.1 with TMB-4 (16, 21).
Only three studies (9, 13, 17) tested the effects 
of atropine given alone. The obtained TF values 
against Tabun and Soman with atropine alone ranged 
between 1.1 and 1.5. These results agree with other 
published data on the effect of atropine against Tabun 
and Soman. Those TF values ranged from 0.9 to less 
than 1.6, when OPs were applied s.c. and atropine 
i.p. or i.m. to mice or rats (cf. 23). Therefore we 
took TF=2.0 as the cut-off value when stating that 
a compound (applied with atropine) has a positive 
therapeutic effect.
The antidotal properties of the studied compounds 
might be attributed to several different effects. 
Compounds bearing an oxime group are reactivators 
of the phosphylated AChE. These compounds also 
bind reversibly to AChE, whereby the enzyme is 
protected from OPs. Carbamates are well known 
protectors of AChE, and are therefore recommended 
for pre-treatment against OPs. Atropine, which was 
given together with the studied compounds, is an 
antimuscarinic drug. Quinuclidinium compounds 
also have antimuscarinic properties that might 
have contributed to their antidotal effects. For the 
quinuclidinium compound that has both a carbamate 
and an oxime group (ImQ-4) it is hard to know 
which of the two groups contributed mainly to the 
therapeutic effect.
The testing protocol used in the described studies 
includes probably both the prophylactic and the 
therapeutic effects, because the antidotes were given 
immediately after the OPs. By modifying the protocol, 
it would probably be possible to test these two effects 
separately. We suggest more detailed studies of 
the compounds presented in this paper and of the 
conventional antidotes in order to show whether 
the studied compounds are more effective than the 
conventional antidotes. Comparative studies of two 
groups of compounds should be done under the same 
experimental conditions concerning doses, routes of 
application, animals, and other details of the protocol. 
If the compounds discussed in this paper prove more 
adequate, this might broaden the choice of antidotes 
against Tabun and Soman poisoning.
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Sažetak
PIRIDINIJEVI, IMIDAZOLIJEVI I KINUKLIDINIJEVI SPOJEVI: TOKSIÈNOST I PROTUOTROVNO 
DJELOVANJE NASPRAM NERVNIM OTROVIMA TABUNU I SOMANU
U ovom su radu opisani toksiènost i protuotrovno djelovanje 32-ju spojeva (antidota) koji su se prema 
literaturnim podacima pokazali djelotvornima (kada se primijene uz atropin) pri eksperimentalnom trovanju 
životinja organofosfornim spojevima tabunom i somanom. Terapijski faktor, tj. omjer LD50 organofosfornog 
spoja u prisutnosti i odsutnosti tih antidota bio je jednak ili veæi od 2.0 kada su spojevi testirani na miševima 
ili štakorima. Predlaže se da se ovi spojevi detaljnije istraže usporedo s konvencionalnim antidotima (PAM-2, 
HI-6, toksogonin, TMB-4) da bi se vidjelo bi li oni mogli proširiti izbor spojeva koji su danas na raspolaganju 
u terapiji i prevenciji otrovanja organofosfatima.
KLJUÈNE RIJEÈI: eksperimentalno trovanje; oksimi; organofosforni spojevi; terapijski faktor
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